NEW YORK, July 16, 2026 – Shares of AtaiBeckley Inc. (NASDAQ: ATAI) soared approximately 31% to $7.04 in early trading Thursday following the announcement of a definitive acquisition agreement with Eli Lilly and Co. (NYSE: LLY). The deal, valued at up to $3.8 billion, combines a $6.75 per share cash payment at closing with a contingent value right (CVR) of up to $2.50 per share tied to regulatory and developmental milestones.
With the stock trading at $7.04, just $0.29 above Lilly's cash offer, the market is assigning a preliminary implied value of roughly 11% to the CVR's face value. This gap reflects investor skepticism about the probability of achieving all milestones, particularly given the time value and closing risks. An undiscounted calculation suggests the CVR is currently valued at about $0.29 per share.
Milestone Structure Favors VLS-01
The CVR is heavily weighted toward VLS-01, a DMT buccal film currently in Phase 2b development. VLS-01 accounts for $2.00, or 80%, of the total contingent payment. The first $1.00 milestone requires initiation of Phase 3 trials within four years of closing. The second $1.00 milestone is contingent upon VLS-01 approval and DEA rescheduling within seven years. BPL-003, the company's lead asset with FDA breakthrough therapy designation and already in Phase 3 activities, contributes only $0.50 to the CVR.
This structure implies that Lilly's cash bid captures most of BPL-003's current value. Investors paying above $6.75 are essentially buying exposure to VLS-01's optionality, a program with higher risk but potentially greater reward.
Market Context and Sector Impact
The cash offer of $6.75 per share represents a 26% premium over Wednesday's closing price of $5.36 and a 40% premium over the 30-day average. The companies expect the transaction to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
Lilly Neuroscience President Carole Ho emphasized the urgent need for effective therapies in psychiatry, while AtaiBeckley CEO Srinivas Rao highlighted Lilly's global reach as a catalyst for accelerated development. BMO analyst Evan Seigerman described the target as offering "differentiated exposure in psychiatry," noting Lilly's strategic expansion beyond cardiometabolic drugs.
The sector read-through was mixed. GH Research PLC (NASDAQ: GHRS) gained about 7%, while Compass Pathways PLC (NASDAQ: CMPS) fell roughly 3%, suggesting investors viewed the deal as asset-specific rather than a broad endorsement of the psychedelic therapy space.
Risks and Valuation Considerations
The CVR may expire worthless if clinical trials, regulatory approvals, or DEA rescheduling fail to meet specified deadlines. The market-implied valuation of $0.29 does not account for time value or the probability of closing, and should not be interpreted as a precise probability estimate. For now, the $6.75 cash offer serves as the market anchor, with the additional $0.29 representing current investor confidence in the milestones.
